📊 LIMNW Key Takeaways
Is LIMNW a Good Investment? Thesis Analysis
Liminatus Pharma exhibits critical financial distress with negative stockholders equity of -9.8M, negative operating cash flow of -10.0M, and only 337.7K in cash against 10.3M in liabilities. At current burn rate, the company has approximately 2 weeks of cash runway, creating imminent bankruptcy risk regardless of pipeline potential.
Why Buy LIMNW? Key Strengths
- Pre-revenue biotech stage is typical for drug development companies
- Cash position of 337.7K provides minimal near-term operating flexibility
- Sector (biological products) represents growth market if company survives
LIMNW Investment Risks to Consider
- Negative stockholders equity of -9.8M indicates technical insolvency
- Critically low current ratio of 0.05x - severe liquidity crisis with only $0.05 in current assets per $1 of current liabilities
- Unsustainable cash burn of -10.0M annually with only 2 weeks of cash remaining at current burn rate
- No revenue generation and -10.2M net loss with deteriorating EPS
- Liabilities (10.3M) exceed assets (512.8K) by 20x, indicating inability to meet obligations
Key Metrics to Watch
- Cash position and runway - critical monitoring given 2-week burn timeline
- Debt restructuring or bankruptcy proceedings announcements
- Dilutive financing activity or capital raise announcements
LIMNW Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
LIMNW Profitability Ratios
LIMNW vs Healthcare Sector
How Liminatus Pharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LIMNW Overvalued or Undervalued?
Based on fundamental analysis, Liminatus Pharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LIMNW Balance Sheet & Liquidity
LIMNW 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Liminatus Pharma, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.20 indicates the company is currently unprofitable.
LIMNW Growth Metrics (YoY)
LIMNW Capital Allocation
LIMNW SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Liminatus Pharma, Inc. (CIK: 0001971387)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LIMNW
What is the AI rating for LIMNW?
Liminatus Pharma, Inc. (LIMNW) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are LIMNW's key strengths?
Claude: Pre-revenue biotech stage is typical for drug development companies. Cash position of 337.7K provides minimal near-term operating flexibility.
What are the risks of investing in LIMNW?
Claude: Negative stockholders equity of -9.8M indicates technical insolvency. Critically low current ratio of 0.05x - severe liquidity crisis with only $0.05 in current assets per $1 of current liabilities.
What is LIMNW's revenue and growth?
Liminatus Pharma, Inc. reported revenue of N/A.
Does LIMNW pay dividends?
Liminatus Pharma, Inc. does not currently pay dividends.
Where can I find LIMNW SEC filings?
Official SEC filings for Liminatus Pharma, Inc. (CIK: 0001971387) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LIMNW's EPS?
Liminatus Pharma, Inc. has a diluted EPS of $-0.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LIMNW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Liminatus Pharma, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LIMNW stock overvalued or undervalued?
Valuation metrics for LIMNW: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LIMNW stock in 2026?
Our dual AI analysis gives Liminatus Pharma, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LIMNW's free cash flow?
Liminatus Pharma, Inc.'s operating cash flow is $-10.0M, with capital expenditures of $13.1K.
How does LIMNW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.05 (avg: 2).